Clinical trials utilizing these treatments in early onset T1D patients displayed variable efficacy for maintaining higher C peptide levels with less reliance on exogenous insulin, however, any benefits were only temporary, and treatment was not successful in halting the progression of disease (3–5). Here, INS is linked to type 1 diabetes mellitus.